Summary:
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL,
MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND
TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE
PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA
Qualified Participants Must:
Male or female 18 to 64 years of age
Qualified Participants May Receive:
Compensation for time and travel